Q-omics provides the consensus-scored UGT2B15 profile across patient tissues and cancer cell-line models. UGT2B15 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, UGT2B15 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, UGT2B15 RNA expression shows 11,103 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight OV, COAD, and ESCA as cancer lineages where UGT2B15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT2B15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT2B15 survival associations across molecular data types. UGT2B15 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT2B15 RNA expression–survival associations across cancer types. High UGT2B15 expression shows unfavorable associations in LGG and ACC, but favorable associations in OV, BLCA, SKCM and BRCA. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for UGT2B15 RNA expression.
This table summarizes UGT2B15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for UGT2B15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT2B15 shows lower tumor expression in COAD, CHOL, LIHC, BRCA and READ and higher tumor expression in LUAD. The COAD box plot shows higher UGT2B15 RNA expression in normal versus tumor tissue (log2 FC = −2.803, t-test p < 0.001).
This table shows molecular features associated with UGT2B15 in patient tissues and cancer cell lines. In patient samples, UGT2B15 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, UGT2B15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
